A class of small-molecule therapeutics for hypertension and inflammatory diseases
Epoxyeicosatrienoic acids (EETs) are lipid metabolites that regulate blood pressure and inflammation. EETs are metabolized by soluble epoxide hydrolase (sEH); therefore, inhibition of sEH may treat hypertension and other medical conditions caused by irregularities in blood pressure, vasodilation, endothelial cell function, and inflammation. However, treatments for these conditions, based on this strategy, do not currently exist because the best-known inhibitors of sEH have poor bioavailability. This technology is a class of potent sEH inhibitors with improved biocompatibility. These inhibitors may potentially be used to treat hypertension, metabolic syndrome, atherosclerosis, erectile dysfunction, stroke, diabetes, and aging in humans. Additionally, these inhibitors may be used to treat laminitis disease in horses.
Novel approach to treatment of hypertensionNo treatments for metabolic syndrome currently existImproved bioavailability and potentially improved pharmacokinetic profilePatent Information:Patent Issued (US 8,653,273)Tech Ventures Reference: IR 2436
Treatment for hypertensionTreatment for inflammationTreatment for metabolic syndrome and syndrome XTreatment for erectile dysfunctionTreatment for atherosclerosisTreatment for strokePreventative treatment for stroke and diabetesPotential anti-aging treatment
None
美國
